Noema Pharma Trigeminal Neuralgia? You are not alone
|DATE:||February 11, 2022|
|TIME:||12:00 PM EST|
About The Event
The Research & Development Day will feature presentations from Key Opinion Leaders (KOL’s) Joanna Zakrzewska BDS, MB BChir, MD, FDSRCS, FFDRCSI, FFPM RCA, FHEA (University College London Hospitals) and Coderre, Terence J. PhD (McGill University) who will discuss the latest research in neuropathic pain and trigeminal neuralgia (TN), current treatment landscape, and patients’ expectations. The potential treatment solution for the management of pain associated with trigeminal neuralgia, NOE-101 mGluR5 NAM (basimglurant) will also be discussed.
NOE-101 mGluR5 NAM (basimglurant) is a highly selective, potent, and cell-penetrant negative allosteric modulator of mGlu5 receptors for the management of pain associated with TN. The antinociceptive effect of NOE-101 is explained through the ability to block nuclear membrane glutamate mGlu5 receptors, the receptors that are overexpressed in chronic pain.
The Noema Pharma management team will also provide a company overview and update.
A live question and answer session will follow the formal presentations.